Program
SEL-120
Also written as “RVU120”, “RVU120(SEL120)” and “RVU120 (SEL120)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Primary Myelofibrosis · Myelodysplastic Syndromes, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ryvu Therapeutics | 62 open or running | phase 2since Sep 7, 2021 | Jul 12, 2019 | Dec 2026phase 2 · NCT06987058 |
| GCP-Service International West | 11 open or running | phase 2since Jan 25, 2024 | Jan 25, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 12, 2019First study: phase 1 study in Leukemia, Myeloid, AcuteNew to Ryvu TherapeuticsRyvu Therapeutics · NCT04021368 · 51 enrolled · United States, Poland
- Sep 7, 2021Phase 2 study in RecurrenceRyvu Therapeutics · NCT05052255 · 66 enrolled · Poland, Spain
- Dec 19, 2023Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263 · 98 planned · France, Italy, Poland and more
- Jan 5, 2024Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06268574 · 62 enrolled · France, Italy, Poland and more
- Jan 25, 2024GCP-Service International West's first study: phase 2 study in Low Risk Myelodysplastic SyndromesNew to GCP-Service International WestGCP-Service International West · NCT06243458 · 41 enrolled · France, Germany, Italy and more
- Apr 29, 2024Phase 2 study in Primary MyelofibrosisRyvu Therapeutics · NCT06397313 · 36 enrolled · Italy, Poland
- May 15, 2025Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058 · 14 planned · France, Poland
Ahead
- Dec 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058
- Aug 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263
TargetBeta
“The hydrochloride salt form of romaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), ”NCIt, by rule
Other programs on CDK8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| romaciclibrule | Ryvu Therapeutics | phase 2 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06987058Leukemia, Myeloid, Acute · France, Poland | 2 | By invitation | Ryvu Therapeutics | Dec 2026 | 14 |
| NCT06397313Primary Myelofibrosis · Italy, Poland | 2 | Terminated | Ryvu Therapeutics | Jun 30, 2026 | 36 |
| NCT06243458Low Risk Myelodysplastic Syndromes · France, Germany, Italy and more | 2 | Active, not recruiting | GCP-Service International West | May 2026 | 41 |
| NCT06268574Leukemia, Myeloid, Acute · France, Italy, Poland and more | 2 | Terminated | Ryvu Therapeutics | Jun 30, 2025 | 62 |
| NCT06191263Leukemia, Myeloid, Acute · France, Italy, Poland and more | 2 | Recruiting | Ryvu Therapeutics | Aug 2027 | 98 |
| NCT05052255Recurrence · Poland, Spain | 2 | Terminated | Ryvu Therapeutics | Oct 2, 2025 | 66 |
| NCT04021368Leukemia, Myeloid, Acute · United States, Poland | 1 | Terminated | Ryvu Therapeutics | May 21, 2024 | 51 |
How it is read
Names in the registry
- “RVU120”, 5 entries
- “RVU120(SEL120)”, 1 entry
- “RVU120 (SEL120)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 4 studies
- Primary Myelofibrosis, 1 study
- Myelodysplastic Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.